Last reviewed · How we verify
Hyper-Diluted Botox
Hyper-diluted botulinum toxin blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions, potentially at lower concentrations than standard Botox formulations.
Hyper-diluted botulinum toxin blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions, potentially at lower concentrations than standard Botox formulations. Used for Investigational formulation; specific Phase 2 indications not publicly detailed.
At a glance
| Generic name | Hyper-Diluted Botox |
|---|---|
| Sponsor | Steve Yoelin M.D. Medical Associates, Inc. |
| Drug class | Botulinum toxin type A |
| Target | SNARE complex (synaptosomal-associated protein) |
| Modality | Small molecule |
| Therapeutic area | Aesthetics / Neurology |
| Phase | Phase 2 |
Mechanism of action
Botulinum toxin type A cleaves SNARE proteins required for acetylcholine vesicle release, leading to temporary muscle paralysis. A hyper-diluted formulation may allow for broader distribution or different clinical applications while maintaining the same fundamental mechanism of action at reduced toxin concentrations.
Approved indications
- Investigational formulation; specific Phase 2 indications not publicly detailed
Common side effects
- Injection site pain or bruising
- Headache
- Muscle weakness
- Ptosis or eyelid drooping
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyper-Diluted Botox CI brief — competitive landscape report
- Hyper-Diluted Botox updates RSS · CI watch RSS
- Steve Yoelin M.D. Medical Associates, Inc. portfolio CI